Bioenvision's Evoltra(R) Advertisement Wins Industry Honor
December 05 2006 - 7:00AM
Business Wire
Bioenvision, Inc. (NasdaqGM: BIVN) announced today the
advertisement for its pediatric leukemia drug Evoltra� has been
given the RX Club Show�s �Award of Excellence� for 2006. Founded in
1986 to showcase the top healthcare advertising from around the
world, the RX Club Show is an annual international competition that
honors the best examples of medical advertising and marketing. �We
are proud to be honored with such a prestigious award," said Rob
Bradbury, European Marketing Manager, Bioenvision. �It is peer
recognition of our marketing excellence, and the innovation that
Bioenvision has demonstrated in getting the Evoltra� brand and
messages to our target audience.� Hugh Griffith, Chief Operating
Officer added; �This further demonstrates the quality of our
European sales and marketing organization and our ability to excel
within the industry.� The winning Evoltra� advertisement features a
young boy on a beach being held in the air in his father�s arms.
The caption says �Time 2 keep dreams alive� which symbolizes the
potential for Evoltra� to send a child�s leukemia into remission,
giving him or her the opportunity to get a transplant and lead a
full life. Evoltra� was approved by the European Commission in May
2006 and is available in all 25 countries of the European Union.
About Evoltra� (clofarabine) The European Marketing Authorization
for Evoltra� (clofarabine) is for "the treatment of acute
lymphoblastic leukemia (ALL) in pediatric patients who have
relapsed or are refractory to at least two prior regimens and where
there is no other treatment option anticipated to result in a
durable response. Safety and efficacy have been assessed in studies
of patients less than or equal to 21 years old at initial
diagnosis." Clofarabine is in clinical development for the
treatment of other hematological cancers and solid tumors.
Bioenvision is also conducting Phase I studies of Evoltra� for the
treatment of psoriasis and is planning further worldwide
development of Evoltra� in autoimmune diseases. Evoltra�
(clofarabine) is a next generation purine nucleoside analog.
Bioenvision holds an exclusive worldwide license (excluding U.S.
and Canada) for the cancer applications of clofarabine and an
exclusive worldwide license for all non-cancer indications.
Bioenvision granted an exclusive sublicense to Genzyme Corporation
to develop and commercialize clofarabine for certain cancer
indications in the U.S. and Canada, which Genzyme markets under the
name of Clolar�. Bioenvision originally obtained clofarabine
development and commercialization rights under patents held by
Southern Research Institute. Clofarabine has been granted orphan
drug designation for the treatment of both ALL and AML in the U.S.
and Europe. In Europe, the designation provides marketing
exclusivity for 10 years following Marketing Authorization. About
Bioenvision Bioenvision's primary focus is the acquisition,
development, distribution and marketing of compounds and
technologies for the treatment of cancer. Bioenvision has a broad
pipeline of products for the treatment of cancer, including:
Evoltra�, Modrenal� (for which Bioenvision has obtained regulatory
approval for marketing in the United Kingdom for the treatment of
post-menopausal breast cancer following relapse to initial hormone
therapy), and other products. Bioenvision is also developing
anti-infective technologies, including the OLIGON� technology; an
advanced biomaterial that has been incorporated into various FDA
approved medical devices and Suvus�, an antimicrobial agent
currently in clinical development for refractory chronic hepatitis
C infection. For more information on Bioenvision please visit our
Web site at www.bioenvision.com. Certain statements contained
herein are "forward-looking" statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995). Because
these statements include risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements. Bioenvision,
Inc. (NasdaqGM: BIVN) announced today the advertisement for its
pediatric leukemia drug Evoltra(R) has been given the RX Club
Show's "Award of Excellence" for 2006. Founded in 1986 to showcase
the top healthcare advertising from around the world, the RX Club
Show is an annual international competition that honors the best
examples of medical advertising and marketing. "We are proud to be
honored with such a prestigious award," said Rob Bradbury, European
Marketing Manager, Bioenvision. "It is peer recognition of our
marketing excellence, and the innovation that Bioenvision has
demonstrated in getting the Evoltra(R) brand and messages to our
target audience." Hugh Griffith, Chief Operating Officer added;
"This further demonstrates the quality of our European sales and
marketing organization and our ability to excel within the
industry." The winning Evoltra(R) advertisement features a young
boy on a beach being held in the air in his father's arms. The
caption says "Time 2 keep dreams alive" which symbolizes the
potential for Evoltra(R) to send a child's leukemia into remission,
giving him or her the opportunity to get a transplant and lead a
full life. Evoltra(R) was approved by the European Commission in
May 2006 and is available in all 25 countries of the European
Union. About Evoltra(R) (clofarabine) The European Marketing
Authorization for Evoltra(R) (clofarabine) is for "the treatment of
acute lymphoblastic leukemia (ALL) in pediatric patients who have
relapsed or are refractory to at least two prior regimens and where
there is no other treatment option anticipated to result in a
durable response. Safety and efficacy have been assessed in studies
of patients less than or equal to 21 years old at initial
diagnosis." Clofarabine is in clinical development for the
treatment of other hematological cancers and solid tumors.
Bioenvision is also conducting Phase I studies of Evoltra(R) for
the treatment of psoriasis and is planning further worldwide
development of Evoltra(R) in autoimmune diseases. Evoltra(R)
(clofarabine) is a next generation purine nucleoside analog.
Bioenvision holds an exclusive worldwide license (excluding U.S.
and Canada) for the cancer applications of clofarabine and an
exclusive worldwide license for all non-cancer indications.
Bioenvision granted an exclusive sublicense to Genzyme Corporation
to develop and commercialize clofarabine for certain cancer
indications in the U.S. and Canada, which Genzyme markets under the
name of Clolar(R). Bioenvision originally obtained clofarabine
development and commercialization rights under patents held by
Southern Research Institute. Clofarabine has been granted orphan
drug designation for the treatment of both ALL and AML in the U.S.
and Europe. In Europe, the designation provides marketing
exclusivity for 10 years following Marketing Authorization. About
Bioenvision Bioenvision's primary focus is the acquisition,
development, distribution and marketing of compounds and
technologies for the treatment of cancer. Bioenvision has a broad
pipeline of products for the treatment of cancer, including:
Evoltra(R), Modrenal(R) (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products. Bioenvision is also
developing anti-infective technologies, including the OLIGON(R)
technology; an advanced biomaterial that has been incorporated into
various FDA approved medical devices and Suvus(R), an antimicrobial
agent currently in clinical development for refractory chronic
hepatitis C infection. For more information on Bioenvision please
visit our Web site at www.bioenvision.com. Certain statements
contained herein are "forward-looking" statements (as such term is
defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Specifically, factors that could
cause actual results to differ materially from those expressed or
implied by such forward-looking statements include, but are not
limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the
potential failure of Bioenvision's compounds under development to
prove safe and effective for treatment of disease; uncertainties
inherent in the early stage of Bioenvision's compounds under
development; failure to successfully implement or complete clinical
trials; failure to receive marketing clearance from regulatory
agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that
change Bioenvision's business, structure or projections; the
development of competing products; uncertainties related to
Bioenvision's dependence on third parties and partners; and those
risks described in Bioenvision's filings with the SEC. Bioenvision
disclaims any obligation to update these forward-looking
statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From May 2024 to Jun 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2023 to Jun 2024